PRAMEF29P

Across TCGA pan-cancer cohorts, PRAMEF29P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated PRAMEF29P data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRAMEF29P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRAMEF29P expression acts as an unfavorable survival marker.

BLCA, LUAD, and KIRC are the cancer types where PRAMEF29P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.091	0.722	<.001	144	view →
LUAD	OS	Tertile	All	0.150	0.812	<.001	72	view →
KIRC	OS	Tertile	All	0.532	0.882	.019	18	view →
ESCA	OS	Tertile	II,III,IV	0.280	0.707	.012	18	view →
HNSC	OS	Tertile	All	0.528	0.768	.031	18	view →
STAD	OS	Tertile	All	0.349	0.588	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRAMEF29P–BLCA (OS)

Open the BLCA breakdown →